Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P27635

UPID:
RL10_HUMAN

ALTERNATIVE NAMES:
60S ribosomal protein L10; Laminin receptor homolog; Protein QM; Ribosomal protein L10; Tumor suppressor QM

ALTERNATIVE UPACC:
P27635; A3KQT0; D3DWW6; Q16470; Q2HXT7; Q53FH7; Q6FGN8; Q8TDA5

BACKGROUND:
The protein known as Large ribosomal subunit protein uL16, or 60S ribosomal protein L10, is integral to the ribosome's function in protein synthesis. It contributes to the formation of ribosomes that are actively engaged in translating the genetic code into proteins, a process vital for life. Additionally, its role in embryonic brain development suggests a broader significance in human growth and neurological formation.

THERAPEUTIC SIGNIFICANCE:
Involvement of Large ribosomal subunit protein uL16 in rare cases of Autism and Intellectual developmental disorders points to its critical role in brain function and development. Exploring the functions and mechanisms of Large ribosomal subunit protein uL16 offers promising avenues for developing novel therapeutic interventions for these complex conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.